All In Biotech

Drug Trial Radar · NCT00158041

Subcutaneous Amifostine Safety Study

Open-Label Prospective Trial Evaluating the Toxicities Associated With Subcutaneous Administration of Ethyol (Amifostine) for the Prevention of Radiation-Induced Toxicities

Last checked: Nov 20, 2026Latest source record: Sep 12, 2005 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

452

Actual

Start

Jan 2002

Primary completion

Not stated

Study completion Jan 2005

Sponsor

Lead sponsor
Mt. Sinai Medical Center, MiamiAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
MedImmune LLC
First posted
Sep 12, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Prevention
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Amifostine is a radioprotective drug which is approved by the US FDA for administration prior to each radiation treatment using the intravenous route. The study evaluated the safety of amifostine administered subcutaneously. The four targeted toxicities were nausea/vomiting, hypotension, generalized skin rash, and injection-site skin reactions.

Conditions

  • Head and Neck Cancer
  • Lung Cancer
  • Lymphoma

Interventions

  • Amifostine administered subcutaneouslyDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of nausea/vomiting
  2. Incidence of hypotension
  3. Incidence of generalized skin rash
  4. Incidence of injection-site skin toxicity

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Mt. Sinai Medical Center

    Miami Beach, Florida

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.